Short-Term Safety Evaluation of a Multi-Pressure Dial: A Prospective, Open-label, Non-randomized Study.
Glaucoma treatment
Multi-pressure dial
Multi-pressure glaucoma management
Normal-tension glaucoma
Open-angle glaucoma
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
18
02
2019
pubmed:
29
3
2019
medline:
29
3
2019
entrez:
29
3
2019
Statut:
ppublish
Résumé
Prospective, open-label, non-randomized, single site study to assess the safety and tolerability of a multi-pressure dial. 30 healthy subjects received application of negative pressure (-15 mmHg) in one eye for 30 minutes and ambient atmospheric pressure in the contralateral eye. To evaluate safety, the primary outcome measures included best corrected visual acuity (BCVA), intraocular pressure (IOP) changes from baseline, slit-lamp and dilated fundus examination findings, and rate of adverse events. Exploratory analyses included in this study also evaluated changes from baseline measurement in tear break-up time (TBUT) and RNFL thickness measured by OCT. In addition to baseline screening, subjects underwent testing and negative pressure application on day 0 and returned 1 week after the initial visit for clinical testing. The follow-up visit did not include use of the multi-pressure dial (MPD) but repeated baseline testing and evaluated for adverse events. No adverse events were reported in the study. After short-term wear of the MPD on day 0, there was a minimal but statistically significant increase of half a line (LogMAR) in BCDVA for study eyes; this increase was not present at 1 week. There were no observed changes in cup-disk ratio and TBUT 1 week after the initial testing. There was a statistically significant pressure reduction in both study and fellow eyes at 1 week following the study, but clinical significance has yet to be determined. The MPD, which consists of a pair of goggles connected to a handheld, programmable pump, was well tolerated by subjects enrolled in the study. Key safety parameters remained stable after short-term exposure. The favorable safety results of this study support the safety profile of the MPD and promote further investigation of the device as a potential treatment of glaucoma. Equinox Ophthalmic, Inc. (Newport Beach, CA).
Identifiants
pubmed: 30919318
doi: 10.1007/s40123-019-0181-y
pii: 10.1007/s40123-019-0181-y
pmc: PMC6513913
doi:
Types de publication
Journal Article
Langues
eng
Pagination
279-287Références
Arch Ophthalmol. 2003 Jan;121(1):48-56
pubmed: 12523884
Bull World Health Organ. 2004 Nov;82(11):887-8
pubmed: 15640929
Ophthalmology. 2008 May;115(5):763-8
pubmed: 18452762
Am J Ophthalmol. 2009 Oct;148(4):623-4; author reply 624-5
pubmed: 19782798
Ophthalmology. 2010 Feb;117(2):259-66
pubmed: 19969367
Curr Opin Ophthalmol. 2010 Mar;21(2):106-11
pubmed: 20040876
Curr Opin Ophthalmol. 2012 Mar;23(2):96-104
pubmed: 22249233
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
Br J Ophthalmol. 2015 Jun;99(6):738-45
pubmed: 25488946
Clin Ophthalmol. 2016 Jan 28;10:189-206
pubmed: 26869753